Calcineurin inhibitors: 40 years later, can’t live without
The DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index.
Abstract
Calcineurin inhibitors (CNIs) revolutionized the field of organ transplantation and remain the standard of care 40 years after the discovery of cyclosporine. The early impressive results of cyclosporine in kidney transplant recipients led to its subsequent use in other organ transplant recipients and for treatment of a variety of autoimmune diseases as well. In this review, we examine the discovery of CNIs, their mechanism of action, preclinical and clinical studies with CNIs, and the usage of CNIs in nontransplant recipients. We review the mechanisms of renal toxicity associated with CNIs and the recent efforts to avoid or reduce usage of these drugs. Although minimization strategies are possible, safe, and of potential long-term benefit, complete avoidance of CNIs has proven to be more challenging than initially thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calcineurin inhibitors, including ciclosporin and tacrolimus, inhibit T cell proliferation and activation through targeting IL-2 (58).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [58]
In the citing paper
“Ciclosporin and tacrolimus are immunosuppressants that inhibit calcineurin, a key signaling phosphatase, by binding to their respective immunophilins - cyclophilin and FKBP12 (76).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [76]
In the citing paper
“A major downstream effect is suppression of interleukin (IL)-2 transcription, thereby inhibiting T cells differentiation, survival, and subsequent antibody production and CTL activities via effector TH cells.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [76]
Citations
Cites
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325 · cited 2×
“Regulatory T cells have been shown to be essential for immune tolerance induction in transplantation (16).”
BackgroundTRANSCRIPTION FACTORS OF THE NFAT FAMILY:Regulation and Function
Rao, A., Luo, C., & Hogan, P. G. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.707 · Cited by 2,603 · cited 1×
“scriptional activation of genes encoding cytokines, including IL-2 and IL-4, and CD40 ligand (12).”
BackgroundThe Natural History of Chronic Allograft Nephropathy
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Allen, R. D. M., & Chapman, J. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020009 · Cited by 1,949
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
Creighton, T. E. (1992) · Cited by 1,583
Biological effects of cyclosporin A: A new antilymphocytic agent
Borel, J. F., Feurer, C., Gubler, H. U., & Stähelin, H. (1976) · Agents and Actions · doi:10.1007/bf01973261 · Cited by 1,509 · cited 1×
“Many mechanisms were suggested, including an imbalance between vasoconstrictive and vasodilatory mediators (46), an activation of the renin-angiotensin-aldosterone system (47), an increase in the release of endothelin (5), an increase in free radicals (48), and a sympathetic nerve activation in the native kidneys thro…”
BackgroundPirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Calne, R. Y., Rolles, K., Thiru, S., Mcmaster, P., Craddock, G. N., Aziz, S., White, D. J. G., Evans, D. B., Dunn, D. C., Henderson, R. G., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92440-1 · Cited by 1,083
CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS
Calne, R. Y., Thiru, S., Mcmaster, P., Craddock, G. N., White, D. J. G., Evans, D. B., Dunn, D. C., Pentlow, B. D., & Rolles, K. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91970-0 · Cited by 1,002 · cited 1×
“The nephrotoxicity of cyclosporine, reported by Calne and colleagues in the early human studies, remains a major concern for the medical community today (21).”
BackgroundVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957 · cited 2×
“The cardiovascular and metabolic profiles were better in belatacept groups compared with patients receiving cyclosporine (70).”
BackgroundCostimulation Blockade with Belatacept in Renal Transplantation
Vincenti, F., Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P. F., Solez, K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050085 · Cited by 861
ANTI-ESCHERICHIA COLI ALPHA-HAEMOLYSIN IN CONTROL AND PATIENT SERA
Emody, L., Batai, I., Kerényi, M., Székely, J., & Polyak, L. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90183-0 · Cited by 800
Unilateral Lung Transplantation for Pulmonary Fibrosis
Toronto Lung Transplant Group* (1986) · New England Journal of Medicine · doi:10.1056/nejm198605013141802 · Cited by 655
GYNAECOLOGISTS' ATTITUDES TO ABORTION
Savage, W., & Francome, C. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91922-3 · Cited by 604
Schena, F. P., Pascoe, M. D., Alberu, J., del Carmen Rial, M., Oberbauer, R., Brennan, D. C., Campistol, J. M., Racusen, L., Polinsky, M. S., Goldberg-Alberts, R., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181927a41 · Cited by 583
Durrbach, A., Pestana, J. M., Pearson, T., Vincenti, F., Garcia, V. D., Campistol, J., Del Carmen Rial, M., Florman, S., Block, A., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03016.x · Cited by 570 · cited 1×
“Multiple studies evaluated the effectiveness of belatacept as a maintenance therapy in kidney transplant recipients compared with cyclosporine (70, 71, 77).”
BackgroundHeisel, O., Heisel, R., Balshaw, R., & Keown, P. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00372.x · Cited by 506
Liver Transplantation with Use of Cyclosporin a and Prednisone
Starzl, T. E., Klintmalm, G. B. G., Porter, K. A., Iwatsuki, S., & Schröter, G. P. J. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107303050507 · Cited by 492 · cited 2×
“(24) showed that 10 of the 12 liver transplant patients treated”
BackgroundShibasaki, F., Price, E. R., Milan, D., & McKeon, F. (1996) · Nature · doi:10.1038/382370a0 · Cited by 488 · cited 1×
“Production of IL-2, in particular, stimulates the growth and differentiation of T cells (13).”
BackgroundA Randomized Clinical Trial of Cyclosporine in Cadaveric Renal Transplantation
The Canadian Multicentre Transplant Study Group (1983) · New England Journal of Medicine · doi:10.1056/nejm198310063091401 · Cited by 472
Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial
Ellis, C. N., Fradin, M. S., Messana, J. M., Brown, M. D., Siegel, M. T., Hartley, A. H., Rocher, L. L., Wheeler, S., Hamilton, T. A., Parish, T. G., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101313240501 · Cited by 429 · cited 2×
“Many risk factors play a role in this nephrotoxicity, including the serum concentration of the drug (34).”
BackgroundProtein Serine/Threonine Phosphatases—New Avenues for Cell Regulation
Shenolikar, S. (1994) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.10.110194.000415 · Cited by 427
Transplantation 50 Years Later — Progress, Challenges, and Promises
Sayegh, M. H., & Carpenter, C. B. (2004) · New England Journal of Medicine · doi:10.1056/nejmon043418 · Cited by 425 · cited 2×
“thermore, cyclosporine became the standard therapy to which all subsequent trials with new modalities were to be compared (31).”
BackgroundSelf-citationConvulsions with an Occult Neural-Crest Tumor
(1979) · New England Journal of Medicine · doi:10.1056/nejm197909063011016 · Cited by 404
Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial
Cattran, D. C., Appel, G. B., Hebert, L. A., Hunsicker, L. G., Pohl, M. A., Hoy, W. E., Maxwell, D. R., Kunis, C. L., & Syndrome, F. T. N. A. N. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590041484.x · Cited by 367
Ekberg, H., Bernasconi, C., Tedesco-Silva, H., Vítko, S., Hugo, C., Demirbas, A., Reyes Acevedo, R., Grinyó, J., Frei, U., Vanrenterghem, Y., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02726.x · Cited by 334 · cited 1×
“At 3 y after transplant, the low-dose tacrolimus arm continued to have the highest graft survival rate and the least acute rejection (64).”
Background(1979) · New England Journal of Medicine · doi:10.1056/nejm197909063011015 · Cited by 291
A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome
Ponticelli, C., Rizzoni, G., Edefonti, A., Altieri, P., Rivolta, E., Rinaldi, S., Ghio, L., Lusvarghi, E., Gusmano, R., Locatelli, F., et al. (1993) · Kidney International · doi:10.1038/ki.1993.194 · Cited by 288
Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy
Hanifin, J. M., Ling, M. R., Langley, R., Breneman, D., & Rafal, E. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.109810 · Cited by 286 · cited 3×
“Alternatively, topical tacrolimus is approved for use in atopic dermatitis cases, but it has also been used off-label for other skin disorders, mostly as an alternative to topical glucocorticoids (45).”
BackgroundTacrolimus monotherapy in membranous nephropathy: A randomized controlled trial
Praga, M., For the GRUPO ESPAÑOL DE ESTUDIO DE LA NEFROPATÍA MEMBRANOSA (Members of the Group listed at the end of the paper), Barrio, V., Juárez, G. F., & Luño, J. (2007) · Kidney International · doi:10.1038/sj.ki.5002215 · Cited by 280
Bram, R. J., Hung, D. T., Martin, P. K., Schreiber, S. L., & Crabtree, G. R. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.8.4760 · Cited by 277 · cited 2×
“pathogenesis of acute calcineurin toxicity and thrombotic microangiopathy after transplant (7).”
BackgroundTacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety
Soter, N. A., Fleischer, A. B., Webster, G. F., Monroe, E., & Lawrence, I. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.109817 · Cited by 235 · cited 1×
“Tubulointerstitial injuries classically described as stripped fibrosis and tubular atrophy are multifactorial in origin, resulting from an increase in free radicals (15), an upregulation of TGF-b (16) leading to epithelial to mesenchymal transition (52), or an activation of the reninangiotensin-aldosterone system with…”
BackgroundA Randomized Trial of Inhaled Cyclosporine in Lung-Transplant Recipients
Iacono, A. T., Johnson, B. A., Grgurich, W. F., Youssef, J. G., Corcoran, T. E., Seiler, D. A., Dauber, J. H., Smaldone, G. C., Zeevi, A., Yousem, S. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043204 · Cited by 227 · cited 1×
“(78) conducted a single-center, randomized, double-blind, placebo-controlled trial of inhaled cyclosporine initiated within 6 wk after transplantation and given in addition to systemic immunosuppression.”
BackgroundCYCLOSPORIN A FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN MAN
Powles, R. L., Clink, H., Sloane, J., Barrett, A. J., Kay, H. E. M., & Mcelwain, T. J. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91971-2 · Cited by 211
PROLONGED SURVIVAL OF PIG ORTHOTOPIC HEART GRAFTS TREATED WITH CYCLOSPORIN A
Calne, R. Y., White, D. J. G., Rolles, K., Smith, D. P., & Herbertson, B. M. (1978) · The Lancet · doi:10.1016/s0140-6736(78)90971-6 · Cited by 208
Five-Year Safety and Efficacy of Belatacept in Renal Transplantation
Vincenti, F., Blancho, G., Durrbach, A., Friend, P., Grinyo, J., Halloran, P. F., Klempnauer, J., Lang, P., Larsen, C. P., Mühlbacher, F., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009111109 · Cited by 189 · cited 1×
“Multiple studies evaluated the effectiveness of belatacept as a maintenance therapy in kidney transplant recipients compared with cyclosporine (70, 71, 77).”
BackgroundEXTENSIVE PROLONGATION OF RABBIT KIDNEY ALLOGRAFT SURVIVAL AFTER SHORT-TERM CYCLOSPORIN-A TREATMENT
Green, C., & Allison, A. (1978) · The Lancet · doi:10.1016/s0140-6736(78)90970-4 · Cited by 173
Clinical Review: Topical Ophthalmic Use of Cyclosporin A
Utine, C. A., Stern, M. E., & Akpek, E. K. (2010) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2010.498657 · Cited by 163 · cited 2×
“The main glomerular lesions include global glomerulosclerosis due to secondary ischemia (44) or focal segmental glomerulosclerosis secondary”
BackgroundPharmacology of calcineurin antagonists
Kapturczak, M. H., Meier-Kriesche, H. U., & Kaplan, B. (2004) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.01.018 · Cited by 160 · cited 3×
“pression via inhibition of calcineurin (1).”
BackgroundInfluentialT cell responses in calcineurin A alpha-deficient mice.
Zhang, B. W., Zimmer, G., Chen, J., Ladd, D., Li, E., Alt, F. W., Wiederrecht, G., Cryan, J., O'Neill, E. A., Seidman, C. E., et al. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.2.413 · Cited by 150
Meta-Analysis of Calcineurin-Inhibitor-Sparing Regimens in Kidney Transplantation
Sharif, A., Shabir, S., Chand, S., Cockwell, P., Ball, S. T., & Borrows, R. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111160 · Cited by 136 · cited 2×
“A recent meta-analysis compared CNI-sparing regimens, either through complete avoidance or minimization, to the standard of care, which is CNI-containing regimens (74).”
BackgroundMethodReduced exposure to calcineurin inhibitors in renal transplantation.
van den Hoogen, M., & Hilbrands, L. (2008) · PubMed · Cited by 125
Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies
Serón, D., Moreso, F., Fulladosa, X., Hueso, M., Carrera, M., & Grinyo, J. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00174.x · Cited by 124 · cited 1×
“However, there is an individual susceptibility to chronic nephrotoxicity, as chronic histological changes have been seen with low-dose levels (55), and no significant graft dysfunction was noted in patients exposed to high-dose levels (47).”
BackgroundHistory of the discovery of cyclosporin and of its early pharmacological development.
Borel, J. F. (2002) · PubMed · Cited by 123
The history of cyclosporin A (Sandimmune®) revisited: Another point of view
Stähelin, H. (1996) · Cellular and Molecular Life Sciences · doi:10.1007/bf01922409 · Cited by 120 · cited 1×
“The method to measure cyclosporine blood levels was developed at the same time (17).”
MethodNEUROSENSORY ADVERSE EFFECTS AFTER PHENYLBUTAZONE AND MISOPROSTOL COMBINED TREATMENT
Jm, J., Lassoued, S., Laroche, M., & Mazières, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91896-5 · Cited by 119
In vitro effects of cyclosporine a and tacrolimus on regulatory T-cell proliferation and function
Miroux, C., Morales, O., Ghazal, K., Othman, S. B., de Launoit, Y., Pancré, V., Conti, F., & Delhem, N. (2012) · Transplantation · doi:10.1097/tp.0b013e3182590d8f · Cited by 117
Biological effects of cyclosporin A: A new antilymphocytic agent
Borel, J. F., Feurer, C., Gubler, H. U., & Stähelin, H. (1994) · Inflammation Research · doi:10.1007/bf01986686 · Cited by 113
Mulay, A. V., Cockfield, S. M., Stryker, R., Fergusson, D. A., & Knoll, G. A. (2006) · Transplantation · doi:10.1097/01.tp.0000237101.58974.43 · Cited by 105
Ishikura, K., Ikeda, M., Hamasaki, Y., Hataya, H., 宍戸, 清., 浅沼, 宏., Nishimura, G., Hiramoto, R., & Honda, M. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.04.076 · Cited by 101 · cited 1×
“Severe additional symptoms may be present shortly after starting cyclosporine and include seizures, encephalopathy, extrapyramidal syndrome, or posterior leukoencephalopathy (57).”
BackgroundProtein folding: Prolyl isomerases join the fold
Schmid, F. X. (1995) · Current Biology · doi:10.1016/s0960-9822(95)00197-7 · Cited by 99 · cited 1×
“Tubulointerstitial injuries classically described as stripped fibrosis and tubular atrophy are multifactorial in origin, resulting from an increase in free radicals (15), an upregulation of TGF-b (16) leading to epithelial to mesenchymal transition (52), or an activation of the reninangiotensin-aldosterone system with…”
BackgroundFørre, Ø., Bjerkhoel, F., Salvesen, C. F., Berg, K. J., Rugstad, H. E., Saelid, G., Mellbye, O. J., & Kåss, E. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780300112 · Cited by 90
Polylactide‐cyclosporin A nanoparticles for targeted immunosuppression
Azzi, J. R., Tang, L., Moore, R. F., Tong, R., Haddad, N. E., Akiyoshi, T., Mfarrej, B. G., Yang, S., Jurewicz, M. M., Ichimura, T., et al. (2010) · The FASEB Journal · doi:10.1096/fj.10-154690 · Cited by 89 · cited 2×
“sub–100-nm sizes, narrow particle size distributions, and release CsA in a sustained manner without a “burst”-release effect (80).”
BackgroundSelf-citationGupta, A. K., Brown, M. D., Ellis, C. N., Rocher, L. L., Fisher, G. J., Baadsgaard, O., Cooper, K. D., & Voorhees, J. J. (1989) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(89)70339-x · Cited by 86 · cited 2×
“Although the efficacy was found to be limited in humans with skin diseases, possibly because of an inability to penetrate the stratum corneum (43), current literature supports the efficacy and safety of topical cyclosporine in the treatment of”
BackgroundResult[Cyclosporin in autoimmune diseases].
Fj, F. (1990) · PubMed · Cited by 81
Williams, D., & Haragsim, L. (2006) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2005.11.001 · Cited by 81
Jain, S., Bicknell, G. R., & Nicholson, M. L. (2000) · British journal of surgery · doi:10.1046/j.1365-2168.2000.01576.x · Cited by 67
Nephrotoxicity as a Complication of Antiretroviral Therapy
Valle, R., & Haragsim, L. (2006) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2006.04.011 · Cited by 65
The controversial early history of cyclosporin
Heusler, K., & Pletscher, A. (2001) · Swiss Medical Weekly · doi:10.4414/smw.2001.09702 · Cited by 59 · cited 4×
“As a result, many groups started investigating cyclosporine in animal models and, shortly after, in humans (4).”
BackgroundInfluentialInhibitory Effects of Cyclosporine on Human Regulatory T Cells In Vitro
Miroux, C., Moralès, O., Carpentier, A., Dharancy, S., Conti, F., Boleslowski, E., Podevin, P., Auriault, C., Pancré, V., & Delhem, N. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.08.043 · Cited by 59 · cited 2×
“All anatomical structures of the kidney may be involved: arterial hyalinosis is frequently irreversible owing to prolonged vasoconstriction or the regulation of NFAT and smooth muscle (14).”
BackgroundReduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Krishnamurthi, V. (2008) · Yearbook of Urology · doi:10.1016/s0084-4071(08)79102-4 · Cited by 59
Tang, L., Azzi, J. R., Kwon, M., Mounayar, M., Tong, R., Yin, Q., Moore, R. F., Skartsis, N., Fan, T. M., Abdi, R., et al. (2012) · Journal of Transplantation · doi:10.1155/2012/896141 · Cited by 57 · cited 1×
“Our published and unpublished data in animals show the possibility of using polymeric nanoparticles as a promising drug delivery vehicle for treating diseases with improved efficacy and reduced toxicity (80, 81).”
BackgroundSelf-citationCalcineurin Inhibitor–Induced Nephrotoxicity and Renal Expression of P‐glycoprotein
Joy, M. S., Nickeleit, V., Hogan, S. L., Thompson, B. D., & Finn, W. F. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.6.779 · Cited by 53 · cited 2×
“the roles of exposure to metabolites of CNIs and to local susceptibility to nephrotoxicity have been reviewed previously (56).”
BackgroundImmunosuppression and Immune Monitoring After Renal Transplantation
Zand, M. S. (2005) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2005.00098.x · Cited by 50
Wali, R. K., Mohanlal, V., Ramos, E., Blahut, S., Drachenberg, C., Papadimitriou, J., Dinits, M., Joshi, A., Philosophe, B., Foster, C., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01825.x · Cited by 49
Cyclosporin in Cadaveric Renal Transplantation: One-Year Follow-Up of a Multicentre Trial
European Multicentre Trial Group (1984) · The Journal of Urology · doi:10.1016/s0022-5347(17)50775-2 · Cited by 46
Drug Transforms Transplant Medicine
Kolata, G. B. (1983) · Science · doi:10.1126/science.6407111 · Cited by 38 · cited 1×
“Its addition to the repertoire of immunosuppressive drugs led to a dramatic improvement in the outcome of organ transplant recipients and to its continuous use more than 30 years after its discovery (2, 3).”
BackgroundBagnis, C. I., Deray, G., Dubois, M., Adabra, Y., Jacquiaud, C., Jaudon, M. C., & Jacobs, C. (1997) · American Journal of Nephrology · doi:10.1159/000169066 · Cited by 38
Treatment of idiopathic nephrosis by immunophillin modulation
Meyrier, A. Y. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg1067 · Cited by 36 · cited 1×
“The use of cyclosporine in patients with either steroid-dependent or -resistant minimal change disease revealed a response rate of 60 and 20%, respectively (38).”
BackgroundCostimulation Blockade with Belatacept in Renal Transplantation
Dharnidharka, V. R. (2005) · New England Journal of Medicine · doi:10.1056/nejm200511103531919 · Cited by 35
Cyclosporine Treatment of Glomerular Diseases
Klein, M., Radhakrishnan, J., & Appel, G. B. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.1 · Cited by 34 · cited 1×
“Cyclosporine was later tried in different forms of nephritic syndrome, including IgA nephropathy, membranoproliferative glomerulonephritis, and lupus nephritis (42).”
BackgroundRole of Maintenance Immunosuppressive Regimen in Kidney Transplant Outcome
Goldfarb‐Rumyantzev, A. S., Smith, L. D., Shihab, F. S., Baird, B. C., Habib, A. N., Lin, S.-J., & Barenbaum, L. L. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00640805 · Cited by 28 · cited 1×
“either no difference in allograft survival (65) or improved allograft survival with cyclosporine (66).”
BackgroundSonoda, T., Takahara, S., Takahashi, K., Uchida, K., Ohshima, S., Toma, H., Tanabe, K., & Yoshimura, N. (2003) · Transplantation · doi:10.1097/01.tp.0000040867.67360.9f · Cited by 25
Boyer, O., Bidois, J. L., Déchaux, M., Gübler, M.-C., & Niaudet, P. (2005) · Transplantation · doi:10.1097/01.tp.0000156990.11135.60 · Cited by 25
Renal Graft Survival and Calcineurin Inhibitor
Woodward, R. S., Menclova, A., Schnitzler, M. A., & Brennan, D. C. (2005) · Transplantation · doi:10.1097/01.tp.0000184842.01686.ca · Cited by 24 · cited 1×
“either no difference in allograft survival (65) or improved allograft survival with cyclosporine (66).”
BackgroundDomain II of calmodulin is involved in activation of calcineurin
Hurwitz, M. Y., Putkey, J. A., Klee, C. B., & Means, A. R. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)80230-8 · Cited by 18
Belatacept: a new era of immunosuppression?
El‐Charabaty, E., Geara, A. S., Ting, C., El‐Sayegh, S., & Azzi, J. R. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.42 · Cited by 15 · cited 1×
“Food and Drug Administration for use in kidney transplant recipients (76).”
BackgroundSelf-citationMeyer, K. C. (2013) · F1000Prime Reports · doi:10.12703/p5-16 · Cited by 15
Multicenter Impact of Ciclosporin on Cadaver Kidney Graft Survival
Opelz, G. (1986) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000318479 · Cited by 14 · cited 1×
“Later, the European Collaborative study reported on results from 200 transplant centers that used cyclosporine that showed the superiority of a cyclosporine-based regimen in graft and patient survival (27).”
ResultCyclosporine and rheumatoid arthritis
Førre, Ø. T., Waalen, K., Rugstad, H. E., Berg, K. J., Solbus, D., & Kåss, E. (1988) · Springer Seminars in Immunopathology · doi:10.1007/bf01857229 · Cited by 12 · cited 1×
“Herrmann and Mueller used cyclosporine for a heterogeneous group of polyarthropathies, including psoriasis and rheumatoid arthritis (RA), with encouraging results (32).”
BackgroundUtine, C. A., & Utine, C. A. (2011) · Clinical ophthalmology · doi:10.2147/opth.s13785 · Cited by 12
The natural history of an HLA haplotype and its recombinants
D’Alfonso, S., Borelli, I., Dall’Omo, A. M., Bolognesi, E., Partanen, J., Levo, A., Pociot, F., Fan, L., Juji, T., Hammond, M., et al. (1998) · Immunogenetics · doi:10.1007/s002510050394 · Cited by 10 · cited 1×
“With regard to the renal tubules, tubular dysfunction includes hyperkalemia due to aldosterone resistance (50) and a decrease in the Na(1)/K(1) ATPase pump (43), hypomagnesemia due to a decreased expression of paracellin 1 in the thick ascending loop of Henle (45), and hyperuricemia due to a decrease in uric acid tubu…”
BackgroundEarly results of cardiac transplantation at the Texas Heart Institute.
Reece, I. J., Frazier, O. H., Painvin, A., Okereke, O. U. J., Chandler, L., Krudewig, T. W., & Cooley, D. A. (1984) · Thorax · doi:10.1136/thx.39.9.676 · Cited by 4
Cyclosporine treatment in patients with primary glomerular diseases.
Tejani, A. H. (1987) · PubMed · Cited by 4
[Unilateral lung transplantation--a new perspective in the treatment of pulmonary fibrosis].
Schäfers, H., Haverich, A., Wagner, T. O., Mm, H., Wahlers, T., Heublein, B., Fabel, H., & Hg, B. (1990) · PubMed · Cited by 2
[Histories of the history of women].
Borello, B. (1999) · PubMed · Cited by 2
Calne, R. Y. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92685-x · Cited by 2
Research works printed but not linked: 1
- Klee, 1988, Calcineurin, Adv. Enzymol. Relat. Areas Mol. Biol., 61, 149
Cited by
Loomba, R., & Liang, T. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.009 · Cited by 594
“Immunophilin inhibitors, such as cyclosporine, suppress T-lymphocyte functions by binding to immunophilins and inhibiting interleukin production.(59) Thus, it is not surprising that these general immunosuppressive effects lead to broad immune dysfunctions and potential HBV reactivation.”
BackgroundRole of Mitochondrial Calcium and the Permeability Transition Pore in Regulating Cell Death
Bauer, T. M., & Murphy, E. (2020) · Circulation Research · doi:10.1161/circresaha.119.316306 · Cited by 439
Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Decourt, B., Lahiri, D. K., & Sabbagh, M. N. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666160930110551 · Cited by 371
Store-Operated Ca2+ Entry Controls Clonal Expansion of T Cells through Metabolic Reprogramming
Vaeth, M., Maus, M., Klein-Hessling, S., Freinkman, E., Yang, J., Eckstein, M., Cameron, S., Turvey, S. E., Serfling, E., Berberich-Siebelt, F., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.003 · Cited by 276
“12 Immunity 47, 1–16, October 17, 2017 long use of CsA and tacrolimus, a satisfying understanding of the molecular mechanism by which calcineurin inhibition regulates T cell proliferation is missing (Azzi et al., 2013).”
InfluentialStrzelec, M., Detka, J., Mieszczak, P., Sobocińska, M. K., & Majka, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127704 · Cited by 233
Metadata
- Authors
- Azzi, J. R., Sayegh, M. H., & Mallat, S. G.
- Affiliations
- Brigham and Women's Hospital (US)
- American University of Beirut (LB)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12
- Volume
- 191
- Issue
- 12
- Pages
- 5785-5791
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1592567691
- Cited by
- 337
- References
- 90
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 26 · 2023: 32 · 2022: 44 · 2021: 38 · 2020: 27 · 2019: 27 · 2018: 25 · 2017: 17 · 2016: 25 · 2015: 14 · 2014: 12
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- calcineurin inhibitors, cyclosporine, tacrolimus, organ transplantation, immunosuppression, nephrotoxicity, drug toxicity reduction, autoimmune disease therapy, mechanism of action
- MeSH terms
- Animals, Autoimmune Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Drug Therapy, Combination, Forecasting, Graft Rejection, Humans, Immunosuppressive Agents, Kidney Diseases, Lymphocyte Activation, T-Lymphocytes, Meta-Analysis as Topic, Multicenter Studies as Topic, Kidney Transplantation, Randomized Controlled Trials as Topic, Tacrolimus, Cyclosporine, Calcineurin, History, 20th Century, History, 21st Century, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.